PBE
PBE
About Invesco Biotechnology & Genome ETF
The Invesco Biotechnology & Genome ETF (Fund) is based on the Dynamic Biotech & Genome Intellidex Index (Index). The Fund will normally invest at least 90% of its total assets in the securities that comprise the Index. The Index is designed to provide capital appreciation by thoroughly evaluating companies based on a variety of investment merit criteria, including price momentum, earnings...
About Invesco Biotechnology & Genome ETF
The Invesco Biotechnology & Genome ETF (Fund) is based on the Dynamic Biotech & Genome Intellidex Index (Index). The Fund will normally invest at least 90% of its total assets in the securities that comprise the Index. The Index is designed to provide capital appreciation by thoroughly evaluating companies based on a variety of investment merit criteria, including price momentum, earnings...
HOLDINGS (Top 20)
| Stock | Name | Weight | Shares | Market Value |
|---|---|---|---|---|
 UTHR | United Therapeutics Corporation | 6.21% | 27.21K | $15.72M |
 ILMN | Illumina, Inc. | 5.48% | 104.83K | $13.87M |
 ALNY | Alnylam Pharmaceuticals, Inc. | 5.10% | 38.71K | $12.90M |
 REGN | Regeneron Pharmaceuticals, Inc. | 4.97% | 16.68K | $12.58M |
 INCY | Incyte Corporation | 4.89% | 127.50K | $12.38M |
 GILD | Gilead Sciences, Inc. | 4.82% | 87.26K | $12.20M |
 BIIB | Biogen Inc. | 4.71% | 66.03K | $11.92M |
 AMGN | Amgen Inc. | 4.63% | 33.65K | $11.72M |
 BCRX | BioCryst Pharmaceuticals, Inc. | 3.44% | 923.46K | $8.72M |
 PTGX | Protagonist Therapeutics, Inc. | 3.35% | 80.42K | $8.48M |
 TGTX | TG Therapeutics, Inc. | 3.15% | 230.34K | $7.97M |
 ARWR | Arrowhead Pharmaceuticals, Inc. | 3.09% | 110.37K | $7.83M |
 RPRX | Royalty Pharma plc | 2.98% | 154.79K | $7.54M |
 CPRX | Catalyst Pharmaceuticals, Inc. | 2.97% | 290.51K | $7.51M |
 PTCT | PTC Therapeutics, Inc. | 2.96% | 101.88K | $7.50M |
 TECH | Bio-Techne Corporation | 2.82% | 122.00K | $7.14M |
 NBIX | Neurocrine Biosciences, Inc. | 2.79% | 53.66K | $7.05M |
 EXEL | Exelixis, Inc. | 2.72% | 155.68K | $6.89M |
 RGEN | Repligen Corporation | 2.72% | 52.18K | $6.88M |
 HALO | Halozyme Therapeutics, Inc. | 2.68% | 99.88K | $6.80M |
SECTOR HOLDINGS
Healthcare
Financial Services
Cash & OthersASSET ALLOCATION BY REGION
United States
NetherlandsSECTOR HOLDINGS
Healthcare Financial Services Cash & OthersASSET ALLOCATION BY REGION
United States NetherlandsHoldings (Top 20)
UTHR
United Therapeutics Corporation
ILMN
Illumina, Inc.
ALNY
Alnylam Pharmaceuticals, Inc.
REGN
Regeneron Pharmaceuticals, Inc.
INCY
Incyte Corporation
GILD
Gilead Sciences, Inc.
BIIB
Biogen Inc.
AMGN
Amgen Inc.
BCRX
BioCryst Pharmaceuticals, Inc.
PTGX
Protagonist Therapeutics, Inc.
TGTX
TG Therapeutics, Inc.
ARWR
Arrowhead Pharmaceuticals, Inc.
RPRX
Royalty Pharma plc
CPRX
Catalyst Pharmaceuticals, Inc.
PTCT
PTC Therapeutics, Inc.
TECH
Bio-Techne Corporation
NBIX
Neurocrine Biosciences, Inc.
EXEL
Exelixis, Inc.
RGEN
Repligen Corporation
HALO
Halozyme Therapeutics, Inc.